Efficacy and safety of single-inhaler triple therapy of glycopyrronium formoterol and fluticasone in patients with COPD: a double-blind randomised controlled trial

摘要

The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 μg glycopyrronium (GB)/12 μg formoterol fumarate (FF)/250 μg fluticasone propionate (FP), compared to 50 μg GB co-administered with a fixed dose of 12 μg FF/250 μg FP in subjects with COPD.